Jazz Pharmaceuticals Announces Third Quarter 2009 Financi...(----- --- SOURCE Jaz...),Health

Date:11/5/2009

----- --- Total assets $102,172 $117,498 ======== ======== LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable $5,240 $5,736 Accrued liabilities 21,370 19,024 Line of credit 3,000 3,875 Senior secured notes - 118,534 Purchased product rights liability 6,000 14,000 Deferred revenue 2,500 12,322 ----- ------ Total current liabilities 38,110 173,491 Deferred rent 7 - Purchased product rights liability, noncurrent 10,000 - Deferred revenue, noncurrent 10,476 11,330 Liability under government settlement, noncurrent 10,658 13,063 Senior secured notes 115,363 - Common stock subject to repurchase - 12,492 Total stockholders' deficit (82,442) (92,878) ------- ------- Total liabilities and stockholders' deficit $102,172 $117,498 ======== ========

SOURCE Jazz Pharmaceuticals, Inc.

'/>"/>

SOURCE Jazz Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate